Dr. Lal PathLabs Q2 FY27 results: what the company reported
Dr. Lal PathLabs Limited, a diagnostics company with a nationwide network of labs and collection centres, filed its unaudited results for the quarter ended 30 September 2026 (July to September 2026, called Q2 FY27) with NSE on the afternoon of 4 November 2026, after a board meeting held the same day.
Published 6 November 2026 · Potoos Research Services
In short. For July to September 2026, Dr. Lal PathLabs reported consolidated revenue from operations of Rs 8,739 million (about Rs 874 crore), up +19.6% from Rs 7,306 million a year earlier. Consolidated profit for the period was Rs 1,939 million, up +27.4% from Rs 1,522 million. The board declared a second interim dividend of Rs 5 per share, with a record date of 11 November 2026.
The numbers
The first two tables are consolidated, from the company’s statement of consolidated results. Dr. Lal PathLabs reports in Rs million (it writes INR million), so the figures are copied as filed; ten million make one crore, so Rs 8,739 million is Rs 873.9 crore. The change column is worked out by us from the filing’s own numbers.
| Item | Jul to Sep 2026 | Jul to Sep 2025 | Change |
|---|---|---|---|
| Revenue from operations | 8,739 | 7,306 | +19.6% |
| Total income (revenue and other income) | 9,082 | 7,554 | +20.2% |
| Profit before tax | 2,605 | 2,036 | +27.9% |
| Profit for the period | 1,939 | 1,522 | +27.4% |
| Profit attributable to owners of the company | 1,922 | 1,506 | +27.6% |
| EPS, basic (Rs; 2025 restated for the bonus issue) | 11.51 | 9.03 | +27.5% |
| Item | Apr to Sep 2026 | Apr to Sep 2025 | Change |
|---|---|---|---|
| Revenue from operations | 16,716 | 14,004 | +19.4% |
| Total income | 17,378 | 14,533 | +19.6% |
| Profit for the period | 3,644 | 2,862 | +27.3% |
| Profit attributable to owners of the company | 3,617 | 2,830 | +27.8% |
| EPS, basic (Rs; 2025 restated for the bonus issue) | 21.65 | 16.97 | +27.6% |
There were no exceptional items in the quarters or half years shown. Of the quarter’s profit of Rs 1,939 million, Rs 17 million belonged to outside shareholders in subsidiaries the company does not fully own (non-controlling interest). EPS is not annualised for quarters.
Why last year’s EPS looks lower than what was reported then. The company issued bonus shares in the ratio 1:1 (one new share for each share held) in December 2025, allotting 8,37,75,510 bonus shares on 22 December 2025. Under the accounting rules, EPS for July to September 2025 has been restated to give effect to the bonus shares, so Rs 9.03 is the comparable figure. The bonus issue did not change profit.
Against the previous quarter (April to June 2026), consolidated revenue from operations was higher: Rs 8,739 million against Rs 7,977 million, a change of +9.6%. Consolidated profit for the period was Rs 1,939 million against Rs 1,705 million, a change of +13.7%.
Dr. Lal PathLabs Limited on its own (standalone)
The company also filed standalone results, for Dr. Lal PathLabs Limited alone without its subsidiaries. Also in Rs million, as filed:
| Item | Jul to Sep 2026 | Jul to Sep 2025 | Change |
|---|---|---|---|
| Revenue from operations | 8,321 | 6,996 | +18.9% |
| Total income | 8,660 | 7,224 | +19.9% |
| Profit for the period | 1,797 | 1,457 | +23.3% |
| EPS, basic (Rs; 2025 restated for the bonus issue) | 10.75 | 8.73 | +23.1% |
| Item | Apr to Sep 2026 | Apr to Sep 2025 | Change |
|---|---|---|---|
| Revenue from operations | 15,965 | 13,403 | +19.1% |
| Total income | 16,603 | 13,894 | +19.5% |
| Profit for the period | 3,456 | 2,750 | +25.7% |
| EPS, basic (Rs; 2025 restated for the bonus issue) | 20.69 | 16.48 | +25.5% |
The dividend
The board declared a second interim dividend for 2026-27 of Rs 5 per share of face value Rs 10 (50% of face value). The record date is 11 November 2026, and the dividend will be paid within 30 days of its declaration. The notes add that an earlier interim dividend of Rs 5 per share for 2026-27 was approved on 24 July 2026 and paid on 11 August 2026.
Shares bought on the record date itself do not count. To see why, read our answer on record dates and when a purchase counts.
What the company said
The company’s press release, filed with NSE on 4 November 2026, carries this headline:
“Dr Lal PathLabs Limited records revenue of Rs 874 Cr with a growth of 19.6% in Q2 FY27”
Dr. Lal PathLabs Limited, press release, 4 November 2026
The Rs 874 crore is the Rs 8,739 million of revenue from operations in the results, rounded. The notes to the results also say:
- During the half year the company bought 100% of Shahbazkers Diagnostic Centre Private Limited on 1 May 2026 for Rs 200 million in cash, and its Dubai subsidiary bought an 80% stake in Sunshine Healthcare Limited in Ghana, which the auditors list as a step-down subsidiary from 4 August 2026. Both businesses are in the 2026 figures.
- The purchase of a 70% stake in SN Genelab Private Limited, a genomics diagnostics company, for up to Rs 1,680 million in cash plus a performance-linked amount capped at Rs 315 million, was completed on 1 October 2026, after the quarter ended. It is not in these figures.
At the same meeting, the board appointed Ms. Vasuta Agarwal as an additional, independent director for three years, subject to shareholder approval, and approved a further investment of up to Rs 49.5 crore in its Dubai subsidiary, Dr. Lal PathLabs FZCO.
What the auditors said
The figures are unaudited. The statutory auditors, Deloitte Haskins & Sells LLP, carried out a limited review, which is lighter than a full audit, and the company’s notes say they expressed an unmodified conclusion. The consolidated report notes that six subsidiaries and one associate were included on figures certified by management and not reviewed by auditors, which management told them are not material to the group. It says its conclusion is not modified in respect of this matter.
Dates
- Board meeting: 4 November 2026, from 11:49 to 13:20 IST.
- Filed with NSE: 4 November 2026 at 13:29 IST. The press release followed at 14:16 IST.
- Dividend record date: 11 November 2026. Payment within 30 days of declaration.
Consolidated and standalone: consolidated figures add up Dr. Lal PathLabs Limited and its subsidiaries, such as Paliwal Diagnostics, as one group. Standalone figures cover Dr. Lal PathLabs Limited alone.
Bonus issue: free extra shares given to existing shareholders. A 1:1 bonus doubles the number of shares, so profit per share halves, and the company restates last year’s EPS so the two years can be compared.
Interim dividend and record date: an interim dividend is paid during the year, before the annual accounts. The record date is the day the company checks its list of shareholders to decide who gets it.
Rs million: ten lakh rupees. Ten million make one crore.
Q2 FY27: the second quarter of the financial year that runs from April 2026 to March 2027.
Sources
- Dr. Lal PathLabs Limited, outcome of board meeting with unaudited standalone and consolidated results, limited review reports and the interim dividend, 4 November 2026. nsearchives.nseindia.com
- Dr. Lal PathLabs Limited, press release on unaudited financial results, 4 November 2026. nsearchives.nseindia.com
This page was written by Potoos Research Services, a SEBI-registered Research Analyst (INH000027380) in Chennai. Every figure above is copied from the company’s filing or, where the page says so, from its press release. Every percentage change in the tables, and any subtotal marked as ours, is worked out by us from the filing’s own numbers.
This page reports what the company filed. It is not a recommendation to buy, sell or hold.
Common questions
What was Dr. Lal PathLabs’ revenue in Q2 FY27?
Consolidated revenue from operations for July to September 2026 was Rs 8,739 million (about Rs 874 crore), against Rs 7,306 million in July to September 2025, a change of +19.6%.
Did Dr. Lal PathLabs’ profit go up in Q2 FY27?
Yes, against a year earlier. Consolidated profit for the period was Rs 1,939 million, against Rs 1,522 million, a change of +27.4%. The owners’ share was Rs 1,922 million, against Rs 1,506 million (+27.6%).
Why is last year’s EPS lower than what the company reported then?
The company issued 1:1 bonus shares in December 2025, which doubled the number of shares. EPS for July to September 2025 has been restated to Rs 9.03 so it can be compared with this year’s Rs 11.51.
What dividend did Dr. Lal PathLabs declare and what is the record date?
A second interim dividend for 2026-27 of Rs 5 per share of face value Rs 10. The record date is 11 November 2026, and the dividend will be paid within 30 days of its declaration.
Is this page a recommendation?
No. It reports what the company filed. It is not a recommendation to buy, sell or hold.